Phase 4 Type 1 Diabetes Trial, Recruiting NCT06699810 Sponsor: Emory University Condition: Type 1 Diabetes
Back to Type 1 Diabetes

Phase 4 Type 1 Diabetes Trial, Recruiting

NCT06699810
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are able and willing to give their informed consent to participate
  • People with a Body Mass Index (BMI) of 28 or higher (a measure of body weight relative to height)
  • People of African American ancestry
  • People who have been diagnosed with diabetic ketoacidosis (DKA), confirmed by specific blood test results showing high blood sugar, low blood acidity, low bicarbonate levels, and elevated ketones (confirm with trial site for exact values)

Who may not be able to join:

  • People with serious medical or surgical conditions, including heart problems, heart failure, chronic vein problems in the legs, chronic kidney problems, liver problems, or active or long-term infections
  • People with uncontrolled hormonal conditions such as excess cortisol (Cushing's syndrome), abnormal growth hormone levels (acromegaly), or an overactive thyroid
  • People with low red blood cell levels (anaemia), bleeding disorders, or problems with blood clotting
  • People who are pregnant
  • People who received a diabetes diagnosis more than 90 days before their current episode of DKA
  • People who are unable to give informed consent

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Principal Investigator: Priyathama Vellanki, MD, MS, Emory University

Phone: (404) 778-1687

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Registry
ClinicalTrials.gov
Start date
23 January 2025
Est. completion
1 January 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Quantify Changes in Blood Glucose; Development of Mathematical Models

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov